BACKGROUND
Mirikizumab, an anti-IL-23p19 monoclonal antibody, has demonstrated clinical efficacy in Crohn's disease (CD), improving symptoms and quality of life (QoL) over one year in the VIVID-1 trial. This analysis from the VIVID-2 open-label extension evaluated its long-term impact on CD symptoms and QoL at two year...
Min-Hu Chen, Ailsa L. Hart, A. Vadhariya et al.· Clinical and Translational G...· 0 citations
BACKGROUND
Monoclonal antibodies targeting the interleukin-23 pathway are effective in treating inflammatory bowel disease. However, these therapies must be administered intravenously or by subcutaneous injection.
METHODS
We conducted a phase 2b, double-blind, randomized trial of oral icotrokinra, a peptide that bloc...
M. Abreu, B. Siegmund, L. Surace et al.· New England Journal of Medic...· 0 citations
Erdheim-Chester disease (ECD) is a rare histiocytic neoplasm driven by MAPK pathway mutations. Although it frequently involves the bones, heart, and kidneys, initial manifestations predominantly affecting the gastrointestinal tract and mesentery are exceedingly rare, often leading to significant delays in clinical di...
Fang-Fang Liu, Meng Zhang, Fei Chen et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.